Sean Whooley

Brookline, Massachusetts

Assistant Editor, Life Sciences at MassDevice

Assistant Editor, Life Sciences at Drug Discovery & Development

Assistant Editor, Life Sciences at Medical Tubing + Extrusion

Assistant Editor, Life Sciences at WTWH Media LLC

Assistant Editor at @MassDevice/@WTWH_Media

Featured in: Favicon

massdevice.com Favicon

drugdiscoverytrends.com Favicon

usnews.com Favicon

miamiherald.com Favicon

washingtontimes.com Favicon

charlotteobserver.com Favicon

kansascity.com Favicon

wtop.com

star-telegram.com Favicon

newsobserver.com + 50 more

Articles

GE HealthCare, Raydiant Oximetry partner on fetal pulse oximetry

1 day ago | massdevice.com | Sean Whooley

GE HealthCare (Nasdaq: GEHC) announced a joint development initiative with Raydiant Oximetry to enhance fetal monitoring capabilities.
BD files patent infringement lawsuit against Baxter over infusion pump tech

2 days ago | massdevice.com | Sean Whooley

BD (NYSE:BDX) has alleged patent infringement by Baxter (NYSE:BAX) in a new legal complaint related to infusion pump technology. Our sister site, Drug Delivery Business News, reports today that BD filed its complaint in the U.S. District Court for the District of Delaware on May 12, 2025, alleging the “infringing manufacture, use, importation, offer for sale, and/or sale” of the Novum IQ infusion system by Baxter. BD and its CareFusion subsidiary provide the Alaris infusion platform.
Tandem subsidiary earns new FDA clearance for insulin infusion set

2 days ago | drugdeliverybusiness.com | Sean Whooley

Tandem Diabetes Care (Nasdaq:TNDM) shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won FDA 510(k) clearance for a new infusion set. The company won clearance for its SteadiSet Infusion Set, according to an SEC Form 8-K. It’s a wearable infusion set that delivers insulin from an insulin pump to the body. San Diego-based Tandem itself develops multiple automated insulin delivery systems, including the flagship t:slim X2 and Mobi miniature durable pump.
Glucotrack can proceed with long-term glucose monitor study

2 days ago | drugdeliverybusiness.com | Sean Whooley

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New Jersey-based Glucotrack develops the CBGM implant that features no on-body external component.
Apreo Health emerges from stealth with positive data for lung scaffold

2 days ago | massdevice.com | Sean Whooley

Apreo Health today announced its emergence from stealth and an upcoming presentation of first-in-human clinical data for its emphysema treatment. Menlo Park, California-based Apreo develops the Breathe airway scaffold. It designed the first-of-its-kind implant to relieve pressure in overinflated lungs without removing or sacrificing healthy tissue. The company says traditional interventions have limitations and carry significant complication rates.
Imperative Care completes enrollment in Symphony PE study

2 days ago | medicaltubingandextrusion.com | Sean Whooley

Imperative Care announced today that it completed enrollment in the SYMPHONY-PE pivotal investigational device exemption (IDE) study. The FDA IDE study evaluates the company’s Symphony Thrombectomy System for treating acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, investigators conducted the study across 19 U.S. centers. Imperative Care designed Symphony to deliver consistent, seamless clot removal in one fully integrated solution.
Imperative Care completes enrollment in pulmonary embolism study

2 days ago | massdevice.com | Sean Whooley

Imperative Care announced today that it completed enrollment in the SYMPHONY-PE pivotal investigational device exemption (IDE) study. The FDA IDE study evaluates the company’s Symphony Thrombectomy System for treating acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, investigators conducted the study across 19 U.S. centers. Imperative Care designed Symphony to deliver consistent, seamless clot removal in one fully integrated solution.
Dexcom promotes Jake Leach to president role

2 days ago | massdevice.com | Sean Whooley

Dexcom (Nasdaq: DXCM) DexCom, Inc. Open 86.674 Day High 86.674 52 Week High 142 52 Week Low 62.34 today announced a significant internal promotion for a longtime member of its leadership team. Our sister site, Drug Delivery Business News, reports today that Jake Leach, the company’s COO, received a promotion to the post of president, too. Leach, who has spent 21 years at Dexcom, originally took over as COO in 2022.
Dexcom promotes Jake Leach to president role

2 days ago | drugdeliverybusiness.com | Sean Whooley

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO. Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments. He joined the company in 2004 to lead the development of sensor electronics for its first commercial continuous glucose monitor (CGM) system.
Synchron announces BCI integration with Apple tech

2 days ago | massdevice.com | Sean Whooley

Synchron announced today that it will become the first brain-computer interface (BCI) maker to achieve native integration with a new Apple protocol. Apple today unveiled its BCI Human Interface Device (BCI HID) profile, enabling the recognition of neural interfaces as a native input category, coming to Apple devices. Users implanted with Synchron’s BCI can control an iPhone, iPad and Apple Vision Pro directly with their thoughts. It requires no physical movement or voice commands.